Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.27 (market cap $8.04B), while YieldMax NVDA Option Income Strategy ETF trades at $12.63. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BIO | NVDY | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $339.75 | $17.96 |
52-Week Low | $241.71 | $12.03 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.43, down 2.51% today, reflecting bearish technical signals with moving averages indicating selling pressure. The fund generates weekly dividends but lacks traditional valuation metrics like P/E or P/S, as it is structured to monetize NVIDIA's volatility through options strategies. Recent news highlights its focus on income generation at the potential cost of capping NVIDIA's upside returns.
The outlook for NVDY hinges on sustained options premium income amid NVIDIA's stock volatility, offering high distribution yields but limiting capital appreciation. Key risks include underperformance versus holding NVIDIA directly, fee drag, and dependency on market conditions for options profitability. Investors seeking income may find value, but growth-oriented investors face significant opportunity cost.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
